Correspondence 0001193125-26-140923 from PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC.
Date: April 2, 2026 · CIK: 0001746473 · Accession: 0001193125-26-140923
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294737
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Mr. Tyler Howes Requested Date: April 6, 2026 Requested Time: 4:15 p.m., Eastern Time
Re: Pliant Therapeutics, Inc.
Dear Mr. Howes:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Pliant Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to April 6, 2026, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marianne Sarrazin at (415) 733-6134.
If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.
Sincerely,
PLIANT THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR April 2, 2026 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Tyler Howes Re: Pliant Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-294737 Acceleration Request Requested Date: April 6, 2026 Requested Time: 4:15 p.m., Eastern Time Dear Mr. Howes: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Pliant Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to April 6, 2026, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marianne Sarrazin at (415) 733-6134. If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134. Sincerely, PLIANT THERAPEUTICS, INC. /s/ Keith Cummings Keith Cummings, MD, MBA Chief Financial Officer cc: Deepa Rich, Esq., Goodwin Procter LLP Marianne Sarrazin, Esq., Goodwin Procter LLP Sam Zucker, Esq., Goodwin Procter LLP